Search
Press release: Theme of the Year and Patient Advocacy - 18th Congress of EHA - European Hematology Association
This year for the first time, the EHA congress program is complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.
Read moreInvitation: “Can EU citizens afford their medicines? The economic crisis and access to medicines in Europe“
For more information, please find the full invitation here
Read moreEHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease
Dates: November 10-12, 2022
Location: Bordeaux, France
Format: Hybrid
Chair: MC Béné
Registration has closed
This was the third time EHA is collaborating with the EHA Specialized Working Group on Diagnosis in hematological diseases, to bring you the latest in laboratory hematology.…
EHA-SWG Scientific Meeting on Integrated Diagnosis Strategies in Oncohematology for the Management of Cytopenias and Leukocytosis
Dates: February 8-10, 2018
Location: Barcelona, Spain
Chair: MC Béné
Co-chair: G Zini
Organized by: EHA & the EHA Scientific Working Group on Diagnosis: Morphology and Flow Cytometry
After a successful first edition in 2015, this meeting returns to Barcelona on February 8-10, 2018.…
EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia
European Hematology Association (EHA) and European Society for Medical Oncology (ESMO) agreed to collaborate on the production of European Guidelines for different hematological malignancies.
Read moreProposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations
This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.
Read moreMajor bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Major bleeding in patients on treatment with NOACs or VKAs in real-life: clinical presentation, management and outcome
Limited data are available on major bleeding (MB) occurring during treatment with vitamin K (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) outside clinical…
ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.
Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- »